NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis $2.87 +0.03 (+1.06%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.88 +0.01 (+0.35%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About XBiotech Stock (NASDAQ:XBIT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XBiotech alerts:Sign Up Key Stats Today's Range$2.85▼$2.9650-Day Range$2.50▼$3.2252-Week Range$2.50▼$8.32Volume27,454 shsAverage Volume172,366 shsMarket Capitalization$87.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Read More XBiotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreXBIT MarketRank™: XBiotech scored higher than 32% of companies evaluated by MarketBeat, and ranked 777th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for XBiotech. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XBiotech is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XBiotech is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXBiotech has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about XBiotech's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.48% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XBiotech has recently decreased by 90.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXBiotech does not currently pay a dividend.Dividend GrowthXBiotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.48% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XBiotech has recently decreased by 90.61%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.27 News SentimentXBiotech has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for XBiotech this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added XBiotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XBiotech insiders have not sold or bought any company stock.Percentage Held by Insiders30.80% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XBiotech's insider trading history. Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIT Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITFebruary 4, 2025 | prnewswire.comXBiotech stock hits 52-week low at $3.5 amid market challengesJanuary 28, 2025 | msn.comIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ years of navigating crashes and crises, he says traditional strategies could soon become wealth destroyers. A time-sensitive briefing reveals what to do now.July 26 at 2:00 AM | InvestorPlace (Ad)XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law FirmJanuary 17, 2025 | prnewswire.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities lawsJanuary 14, 2025 | globenewswire.comXBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law FirmJanuary 13, 2025 | businesswire.comXBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%January 10, 2025 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITJanuary 8, 2025 | prnewswire.comSee More Headlines XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed this year? XBiotech's stock was trading at $3.95 at the start of the year. Since then, XBIT shares have decreased by 27.3% and is now trading at $2.87. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) issued its quarterly earnings data on Wednesday, May, 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter. When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings5/14/2025Today7/26/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XBIT CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.14% Return on Assets-19.55% Debt Debt-to-Equity RatioN/A Current Ratio29.15 Quick Ratio29.15 Sales & Book Value Annual Sales$4.01 million Price / Sales21.82 Cash FlowN/A Price / Cash FlowN/A Book Value$5.98 per share Price / Book0.48Miscellaneous Outstanding Shares30,490,000Free Float21,098,000Market Cap$87.51 million OptionableOptionable Beta0.98 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:XBIT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.